Insights in interception

Four months after launching an R&D group to predict and prevent progression to disease, Janssen Research & Development LLC has revealed the center's first research collaboration in Type I diabetes, named two new disease areas and shared additional details on how it is approaching disease interception.

Johnson & Johnson's Janssen unit established the Disease Interception Accelerator (DIA) in February to ring-fence resources for projects to identify at-risk populations in whom it might be possible to prevent the onset of disease. At the time, the DIA said its first research venture would focus on Type I diabetes...